What it actually is
Put the three pieces back together and you get the plain-language version: a fast-growing mass of immature cells, arising from the brain's own support tissue. Doctors call it a grade 4 tumor — the highest, most aggressive grade there is — and it's the most common primary malignant brain tumor diagnosed in adults.
Why it's so hard to beat
Most solid tumors grow as one contained lump a surgeon can cut around. Glioblastoma doesn't. It sends thin fingers of cells out into the healthy brain tissue surrounding it, well past what any scan can see or any scalpel can safely follow — so even a technically successful surgery is rarely a complete one. The brain's own defense system compounds the problem: the blood-brain barrier that normally keeps toxins out also blocks most chemotherapy drugs from ever reaching the tumor at a useful dose. Nearly every case eventually recurs.
The numbers
Reported figures vary somewhat by study and registry, but the shape of the picture is consistent: median survival after diagnosis is typically in the range of 12 to 18 months, and the five-year survival rate is roughly 5 to 7% — among the lowest of any cancer. Standard treatment — surgical removal followed by combined radiation and chemotherapy, the standard since 2005 — extends time, but there is currently no cure.
Why we run
Rob Shein's standard treatment stopped working in the fall of 2022. What came next wasn't in any protocol — it was Dr. Eric T. Wong, at Rhode Island Hospital, pursuing an approach grounded in basic science because the established playbook had run out. It bought Rob eight more months. That's what a grant won't pay for: the slower, riskier, harder-to-fund science that only gets tried because someone kept looking. This run exists to cover that gap.